|
|
Blood, 15 November 2007, Vol. 110, No. 10, pp. 3715-3721.
Prepublished online as a Blood First Edition Paper on August 6, 2007; DOI 10.1182/blood-2007-05-090142.
Previous Article | Next Article 
Submitted May 14, 2007
Accepted July 30, 2007
Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival
Christoph Mancao and Wolfgang Hammerschmidt*
Department of Gene Vectors, GSF-National Research Center for Environment and Health, Munich, Germany
* Corresponding author; email: hammerschmidt{at}gsf.de.
Many cells latently infected with Epstein-Barr virus (EBV), including certain virus-associated tumors, express latent membrane protein 2A (LMP2A) suggesting an important role for this protein in viral latency and oncogenesis. LMP2A mimics B-cell receptor signaling but can also act as a decoy receptor blocking B-cell receptor (BCR) activation. Studies of peripheral B cells have not resolved this apparent contradiction because LMP2A seems to be dispensable for EBV-induced transformation of these B cells in vitro. We show here that LMP2A is essential for growth transformation of germinal center B cells, which do not express the genuine BCR because of deleterious somatic hypermutations in their immunoglobulin genes. BCR-positive (BCR+) and -negative (BCR-) B cells are readily transformed with a recombinant EBV encoding a conditional, floxed LMP2A allele but the survival and continued proliferation of both BCR+ and BCR- B cells is strictly dependent on LMP2A. These findings indicate that LMP2A has potent, distinct anti-apoptotic and/or transforming characteristics and point to its role as an indispensable BCR mimic in certain B cells from which human B-cell tumors such as Hodgkin's lymphoma originate.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Viral mimic for B-cell survival
- Ralf Küppers
Blood 2007 110: 3494-3495.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
K. T. Bieging, A. C. Amick, and R. Longnecker
Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis
PNAS,
October 20, 2009;
106(42):
17945 - 17950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Shannon-Lowe, E. Adland, A. I. Bell, H.-J. Delecluse, A. B. Rickinson, and M. Rowe
Features Distinguishing Epstein-Barr Virus Infections of Epithelial Cells and B Cells: Viral Genome Expression, Genome Maintenance, and Genome Amplification
J. Virol.,
August 1, 2009;
83(15):
7749 - 7760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Carbone, E. Cesarman, M. Spina, A. Gloghini, and T. F. Schulz
HIV-associated lymphomas and gamma-herpesviruses
Blood,
February 5, 2009;
113(6):
1213 - 1224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Anderson and R. Longnecker
Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo
Blood,
January 1, 2009;
113(1):
108 - 116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Anderson and R. Longnecker
EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway
J. Gen. Virol.,
July 1, 2008;
89(7):
1563 - 1568.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|